Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | IP6K1 | Q92551 | 3/20 | 0.38 |
| ▸ | IP6K3 | Q96PC2 | 3/20 | 0.38 |
| ▸ | IP6K2 | Q9UHH9 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL570621 | 0.82 | ALDH1A1 (0.47) | ALDH1A1KDM4EMEN1KMT2ARBP4 | |
| SCHEMBL4129795 | 0.81 | RBP4 (0.41) | ALDH1A1KDM4EMEN1KMT2ARBP4 | |
| SCHEMBL1756651 | 0.81 | RBP4 (0.41) | ALDH1A1KDM4EMEN1KMT2ARBP4 | |
| SCHEMBL4602617 | 0.81 | LCK (0.47) | ALDH1A1KDM4EMEN1KMT2ARBP4 | |
| SCHEMBL8880128 | 0.80 | RBP4 (0.39) | ALDH1A1KDM4EMEN1KMT2ARBP4 | |
| SCHEMBL17321380 | 0.80 | ELANE (0.40) | ALDH1A1KDM4EMEN1KMT2ARBP4 | |
| SCHEMBL6170975 | 0.80 | RAB9A (0.43) | ALDH1A1KDM4EMEN1KMT2ARBP4 | |
| SCHEMBL8232354 | 0.80 | RBP4 (0.41) | ALDH1A1KDM4EMEN1KMT2ARBP4 | |
| SCHEMBL18703328 | 0.80 | IP6K1 (0.50) | ALDH1A1KDM4EMEN1KMT2ARBP4 | |
| SCHEMBL25174216 | 0.78 | RBP4 (0.40) | ALDH1A1KDM4EMEN1KMT2ARBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-3272357-B2 | — | — | 2002-04-08 | — | — | JP | claimed |
| US-5430148-A | Antiproliferative quinazolines | AGOURON PHARMACEUTICALS, INC. (US) | 1995-07-04 | — | — | US | claimed |
| EP-0637300-A1 | ANTIPROLIFERATIVE QUINAZOLINES | AGOURON PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | claimed |
| WO-1993020055-A1 | ANTIPROLIFERATIVE QUINAZOLINES | AGOURON PHARMACEUTICALS, INC. (US) | 1993-10-14 | — | — | WO | claimed |
| JP-3099045-A | — | — | None | — | — | JP | disclosed |
| WO-2023076218-A1 | SPIROTRICYCLE RIPK1 INHIBITORS AND METHODS OF USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-05-04 | — | — | WO | disclosed |
| US-20220227739-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-07-21 | — | — | US | disclosed |
| CN-108430994-B | Compounds, compositions and methods for modulating CFTR | 蛋白质平衡治疗股份有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11136313-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3359536-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20200385365-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10550106-B2 | Compounds, compositions, and methods for modulating CFTR | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-5707992-A | MICROBIOCIDES, ANTITUMOR AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1998-01-13 | — | — | US | disclosed |
| US-5430148-A | Antiproliferative quinazolines | AGOURON PHARMACEUTICALS, INC. (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0637300-A1 | ANTIPROLIFERATIVE QUINAZOLINES | AGOURON PHARMACEUTICALS, INC. (US) | 1995-02-08 | — | — | EP | disclosed |
| WO-1993020055-A1 | ANTIPROLIFERATIVE QUINAZOLINES | AGOURON PHARMACEUTICALS, INC. (US) | 1993-10-14 | — | — | WO | disclosed |
| JP-H0399045-A | PRODUCTION OF N-(3,4-DIMETHOXYCINNAMOYL)ANTHRANILIC ACID | TOA BOSHOKU KK | 1991-04-24 | — | — | JP | disclosed |
| US-4279823-A | REACTION WITH A THALLIUM SALT THAN WITH A CARBON MONOXIDE IN THE PRESENCE OF A NOBLE METAL CATALYST | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 1981-07-21 | — | — | US | disclosed |
| US-4248622-A | PREEMERGENCE | CHIMAC SOCIETE ANONYME (BE) | 1981-02-03 | — | — | US | disclosed |
| US-4151170-A | Process for the manufacture of indigoid dyes | CIBA-GEIGY AG (CH) | 1979-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11136313-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | ALDH1A1 3790/4885KDM4E 4558/4885MEN1 4387/4885 |
| US-20200385365-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | ALDH1A1 3790/4885KDM4E 4558/4885MEN1 4387/4885 |
| US-20220227739-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1G | ALDH1A1 3790/4885KDM4E 4558/4885MEN1 4387/4885 |
| US-10550106-B2 | Compounds, compositions, and methods for modulating CFTR | CFTR, SCNN1B, SCNN1G | ALDH1A1 3790/4885KDM4E 4558/4885MEN1 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.